Waters Stock Price, News & Analysis

Waters Corporation (NYSE:WAT) reported strong Q2 2025 financial results, with sales reaching $771 million, representing a 9% increase as reported and 8% in constant currency. The company achieved GAAP EPS of $2.47 and non-GAAP EPS of $2.95, exceeding guidance expectations.

Key performance highlights include mid-single-digit instrument growth led by LC and MS segments, and an 11% constant currency growth in recurring revenue. Pharma segment grew 11%, Industrial increased 6%, while Academic & Government declined 3%. Based on strong performance, Waters raised its full-year 2025 guidance, projecting constant currency sales growth of 5.5% to 7.5% and non-GAAP EPS of $12.95 to $13.05.

Waters (NYSE:WAT) and BD have announced a transformative $17.5 billion merger combining BD's Biosciences & Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust transaction. The deal will create a leading life science and diagnostics company with expected 2025 pro forma sales of $6.5 billion and adjusted EBITDA of $2.0 billion.

The merger doubles Waters' total addressable market to $40 billion and increases annual recurring revenue to over 70%. The combined entity expects $345 million in annualized EBITDA synergies by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five. The transaction is expected to be accretive to adjusted EPS in the first year.

Post-merger, Waters' CEO Udit Batra will lead the combined company, which will maintain the Waters name and NYSE:WAT listing. BD shareholders will own 39.2% of the combined company, while Waters shareholders will retain 60.8%. The deal is expected to close around Q1 2026.

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and technologies, has scheduled its Q2 2025 earnings conference call for Monday, August 4th, 2025, at 8:00 a.m. Eastern Time. The presentation will be accessible through a live webcast on the company's investor relations website.

The webcast replay will remain available until September 2nd, 2025. Waters Corporation serves life, materials, food, and environmental sciences sectors with over 7,600 employees operating in more than 100 countries, focusing on medicine efficacy, food safety, water purity, and product quality.

Waters Corporation (NYSE: WAT) has announced Alliance iS HPLC System Software version 2.0, featuring enhanced security and traceability features for pharmaceutical industry applications. The update integrates with Empower Software, providing authenticated user access verification on the onboard touchscreen. Key improvements include individual access control, comprehensive audit trails, and up to 40% reduction in human errors. The system has earned ACT Ecolabels for sustainable practices and will be available from August 2025. Notably, over 80% of novel drugs have been submitted to regulatory authorities using Empower Software, highlighting its industry significance. The integration aims to enhance compliance monitoring and establish new standards for data integrity in QC laboratories.

Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute XR Mass Spectrometer, its most advanced benchtop tandem quadrupole system. The new device delivers up to 6x increase in performance robustness compared to the Xevo TQ Absolute, while offering superior sensitivity for pharmaceutical quantitation and PFAS detection. Key features include 50% reduced power and nitrogen gas consumption, 50% less heat production, and 50% smaller bench space footprint compared to competitors. The system incorporates the innovative StepWave XR Ion Guide technology, designed to minimize downtime while maintaining high sensitivity for complex samples. The product has demonstrated impressive performance at Synexa Life Sciences, handling over 20,000 continuous injections of human plasma samples with enhanced reproducibility and accuracy.

Waters Corporation (NYSE:WAT) has launched BioResolve Protein A Affinity Columns with MaxPeak Premier Technology, marking their first entry into affinity chromatography columns. The innovative product delivers up to 7x improvement in sensitivity compared to market leaders, featuring novel non-porous 3.5 μm particles. Key benefits include: enabling measurements up to 2 days earlier for antibody titers, providing 2x more attribute information with simplified workflows, and allowing accurate quantitation at lower concentrations with less sample. The columns, available in 2.1 x 20 mm and 3.9 x 5 mm formats, can be coupled with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system.

Waters Corporation (NYSE:WAT) has acquired Halo Labs, a company specializing in imaging technologies for particle analysis in therapeutic products. The acquisition brings Halo's Aura™ platform, which offers full spectrum particle analysis capabilities complementary to Waters' existing Wyatt Technology™ Portfolio.

The Aura platform's key advantage lies in its ability to detect translucent process impurities in CAR T-cell therapies that are typically undetectable through standard methods. This technology will be integrated into Waters' large molecule development and QA/QC processes, enhancing their analytical capabilities for biopharmaceutical applications.

The acquisition is expected to have a negligible impact on Waters' income statement over the next 12 months.

Waters Corporation (NYSE:WAT) announced that CEO Udit Batra will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th, 2025, at 8:45AM Eastern Time. The event will be webcast live on Waters' Investor Relations website, with a replay available for 90 days.

Waters Corporation is a global leader in analytical instruments, separations technologies, and software for life, materials, food, and environmental sciences. With over 65 years of experience and 7,600+ employees across 100+ countries, the company collaborates with customers in laboratories, manufacturing sites, and hospitals to advance scientific innovation.

Waters Corporation (NYSE:WAT) has integrated Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments from its Wyatt Technology Portfolio with Empower Software. This integration enables biologics data acquisition and quality control analysis, providing significant benefits: • Reduces software validation time by up to 6 months • Cuts analysis time for biotherapeutic peptides and proteins by 20% • Enhances quality control through absolute molecular weight measurements The integration includes DAWN, miniDAWN, and OptiLab Detectors and will be available in July 2025. Empower Software, used in over 80% of novel drug submissions to regulators, now offers improved efficiency and GMP readiness while reducing end-user training requirements in compliant settings.